相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer The SELECT-1 Randomized Clinical Trial
Pasi A. Janne et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
A meta-analysis of the association between BRAF mutation and nonsmall cell lung cancer
Guanghui Cui et al.
MEDICINE (2017)
Histone deacetylase activity mediates acquired resistance towards structurally diverse HSP90 inhibitors
Ryan C. Chai et al.
MOLECULAR ONCOLOGY (2017)
Targeted agents and immunotherapies: optimizing outcomes in melanoma
Jason J. Luke et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
The HSP90 chaperone machinery
Florian H. Schopf et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2017)
High expression of Rac1 is correlated with partial reversed cell polarity and poor prognosis in invasive ductal carcinoma of the breast
Bingbing Liu et al.
TUMOR BIOLOGY (2017)
BRAF Fusion as a Novel Mechanism of Acquired Resistance to Vemurafenib in BRAFV600E Mutant Melanoma
Atul Kulkarni et al.
CLINICAL CANCER RESEARCH (2017)
Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma
Jean-Pierre Delord et al.
CLINICAL CANCER RESEARCH (2017)
Molecular Targeted Drugs and Treatment of Colorectal Cancer: Recent Progress and Future Perspectives
Fang Geng et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2017)
A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor
Johanna C. Bendell et al.
BRITISH JOURNAL OF CANCER (2017)
BRAF-Mutated Colorectal Cancer: What Is the Optimal Strategy for Treatment?
Romain Cohen et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2017)
Synthesis and Biological Evaluation of Novobiocin Core Analogues as Hsp90 Inhibitors
Katherine M. Byrd et al.
CHEMISTRY-A EUROPEAN JOURNAL (2016)
Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)
Fabrice Barlesi et al.
LANCET (2016)
Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial
David Planchard et al.
LANCET ONCOLOGY (2016)
Treating cancer with selective CDK4/6 inhibitors
Ben O'Leary et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Novel HSP90 inhibitors effectively target functions of thyroid cancer stem cell preventing migration and invasion
Peter T. White et al.
SURGERY (2016)
Impact of point mutation P29S in RAC1 on tumorigenesis
Vidya Rajendran et al.
TUMOR BIOLOGY (2016)
Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation
David S. Hong et al.
CANCER DISCOVERY (2016)
Rac1 overexpression is correlated with epithelial mesenchymal transition and predicts poor prognosis in non-small cell lung cancer
Yujuan Zhou et al.
JOURNAL OF CANCER (2016)
Cutaneous Side Effects of BRAF Inhibitors in Advanced Melanoma: Review of the Literature
Bilgen Gencler et al.
DERMATOLOGY RESEARCH AND PRACTICE (2016)
Resistant mechanisms to BRAF inhibitors in melanoma
Jose Luis Manzano et al.
ANNALS OF TRANSLATIONAL MEDICINE (2016)
A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)
G. R. Blumenschein et al.
ANNALS OF ONCOLOGY (2015)
Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer
T. Macarulla et al.
BRITISH JOURNAL OF CANCER (2015)
Pilot Trial of Combined BRAF and EGFR Inhibition in BRAF-Mutant Metastatic Colorectal Cancer Patients
Rona Yaeger et al.
CLINICAL CANCER RESEARCH (2015)
RAC1 and Melanoma
Ruth Halaban
CLINICAL THERAPEUTICS (2015)
Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers
Sally Temraz et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2015)
BRAF Mutation and Thyroid Cancer Recurrence
Mark Yarchoan et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Immune Checkpoint Blockade in Cancer Therapy
Michael A. Postow et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
RAF inhibitors that evade paradoxical MAPK pathway activation
Chao Zhang et al.
NATURE (2015)
Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia
E. Tiacci et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model
Daniele Perna et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Inhibitors of pan-PI3K signaling synergize with BRAF or MEK inhibitors to prevent BRAF-mutant melanoma cell growth
Melanie Sweetlove et al.
FRONTIERS IN ONCOLOGY (2015)
BRAF kinase domain mutations are present in a subset of chronic myelomonocytic leukemia with wild-type RAS
Liping Zhang et al.
AMERICAN JOURNAL OF HEMATOLOGY (2014)
The RAC1 P29S Hotspot Mutation in Melanoma Confers Resistance to Pharmacological Inhibition of RAF
Ian R. Watson et al.
CANCER RESEARCH (2014)
BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact
Helen Rizos et al.
CLINICAL CANCER RESEARCH (2014)
Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial
Marcia S. Brose et al.
LANCET (2014)
Combination of vemurafenib and cobimetinib in patients with advanced BRAFV600-mutated melanoma: a phase 1b study
Antoni Ribas et al.
LANCET ONCOLOGY (2014)
Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
G. V. Long et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma
James Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy
Hubing Shi et al.
CANCER DISCOVERY (2014)
The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma
Eliezer M. Van Allen et al.
CANCER DISCOVERY (2014)
Extended Antitumor Response of a BRAF V600E Papillary Thyroid Carcinoma to Vemurafenib
Siraj M. Ali et al.
CASE REPORTS IN ONCOLOGY (2014)
Resistance to BRAF Inhibition in BRAF-Mutant Colon Cancer Can Be Overcome with PI3K Inhibition or Demethylating Agents
Muling Mao et al.
CLINICAL CANCER RESEARCH (2013)
The Cell-Cycle Regulator CDK4: An Emerging Therapeutic Target in Melanoma
Karen E. Sheppard et al.
CLINICAL CANCER RESEARCH (2013)
The Therapeutic Target Hsp90 and Cancer Hallmarks
Yoshihiko Miyata et al.
CURRENT PHARMACEUTICAL DESIGN (2013)
Bim, a Proapoptotic Protein, Up-regulated via Transcription Factor E2F1-dependent Mechanism, Functions as a Prosurvival Molecule in Cancer
Raghu Gogada et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic BRAF-Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor
Kevin B. Kim et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma
Paolo A. Ascierto et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study
Pasi A. Jaenne et al.
LANCET ONCOLOGY (2013)
Hepatotoxicity with Combination of Vemurafenib and Ipilimumab
Antoni Ribas et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Selumetinib-Enhanced Radioiodine Uptake in Advanced Thyroid Cancer
Alan L. Ho et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Antitumor Activity of BRAF Inhibitor Vemurafenib in Preclinical Models of BRAF-Mutant Colorectal Cancer
Hong Yang et al.
CANCER RESEARCH (2012)
Intermittent Administration of MEK Inhibitor GDC-0973 plus PI3K Inhibitor GDC-0941 Triggers Robust Apoptosis and Tumor Growth Inhibition
Klaus P. Hoeflich et al.
CANCER RESEARCH (2012)
A Comprehensive Survey of Ras Mutations in Cancer
Ian A. Prior et al.
CANCER RESEARCH (2012)
Targeting the EGFR signaling pathway in cancer therapy
Parthasarathy Seshacharyulu et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2012)
A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma
Simon Pacey et al.
INVESTIGATIONAL NEW DRUGS (2012)
RAS Mutations Are Associated With the Development of Cutaneous Squamous Cell Tumors in Patients Treated With RAF Inhibitors
Patrick A. Oberholzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
The role of BRAF V600 mutation in melanoma
Paolo A. Ascierto et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2012)
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial
Gerald S. Falchook et al.
LANCET (2012)
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
Axel Hauschild et al.
LANCET (2012)
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial
Gerald S. Falchook et al.
LANCET ONCOLOGY (2012)
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial
Georgina V. Long et al.
LANCET ONCOLOGY (2012)
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Anirudh Prahallad et al.
NATURE (2012)
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
Fei Su et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Abstract 2515: Preclinical Development of ARRY-162, A Potent and Selective MEK 1/2 Inhibitor
Patrice A. Lee et al.
CANCER RESEARCH (2011)
Combinatorial Treatments That Overcome PDGFRβ-Driven Resistance of Melanoma Cells to V600EB-RAF Inhibition
Hubing Shi et al.
CANCER RESEARCH (2011)
PTEN Loss Confers BRAF Inhibitor Resistance to Melanoma Cells through the Suppression of BIM Expression
Kim H. T. Paraiso et al.
CANCER RESEARCH (2011)
Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation
Debyani Chakravarty et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
BRIM-2: An open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAF V600E mutation-positive metastatic melanoma.
A. Ribas et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
BRAF Mutations in Hairy-Cell Leukemia
Enrico Tiacci et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Resistance to BRAF Inhibition in Melanomas
David B. Solit et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
Sonja J. Heidorn et al.
CELL (2010)
The First-in-Human Study of the Hydrogen Sulfate (Hyd-Sulfate) Capsule of the MEK1/2 Inhibitor AZD6244 (ARRY-142886): A Phase I Open-Label Multicenter Trial in Patients with Advanced Cancer
Udai Banerji et al.
CLINICAL CANCER RESEARCH (2010)
PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors.
S. Kopetz et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
BRAF Mutation in Papillary Thyroid Carcinoma: Pathogenic Role and Clinical Implications
Kam-Tsun Tang et al.
JOURNAL OF THE CHINESE MEDICAL ASSOCIATION (2010)
A Phase II, Open-Label, Randomized Study to Assess the Efficacy and Safety of AZD6244 (ARRY-142886) Versus Pemetrexed in Patients with Non-small Cell Lung Cancer Who Have Failed One or Two Prior Chemotherapeutic Regimens
John D. Hainsworth et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
Poulikos I. Poulikakos et al.
NATURE (2010)
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
Georgia Hatzivassiliou et al.
NATURE (2010)
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
Cory M. Johannessen et al.
NATURE (2010)
Melanomas acquire resistance toB-RAF(V600E) inhibition by RTK or N-RAS upregulation
Ramin Nazarian et al.
NATURE (2010)
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
BRAF Mutation in Metastatic Colorectal Cancer.
Jolien Tol et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
MEK1 mutations confer resistance to MEK and B-RAF inhibition
Caroline M. Emery et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas
Keiran S. M. Smalley et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
P. J. Roberts et al.
ONCOGENE (2007)
MAP kinase signalling pathways in cancer
A. S. Dhillon et al.
ONCOGENE (2007)
Sorafenib in advanced clear-cell renal-cell carcinoma
Bernard Escudier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
PTEN signaling pathways in melanoma
H Wu et al.
ONCOGENE (2003)
The phosphatidylinositol 3-kinase-AKT pathway in human cancer
I Vivanco et al.
NATURE REVIEWS CANCER (2002)
分享论文
